Published in BMJ on December 16, 2006
Shifting the focus in fracture prevention from osteoporosis to falls. BMJ (2008) 3.27
Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes. BMC Musculoskelet Disord (2007) 1.34
Effective risk assessment tools for osteoporosis in the Indian menopausal female. J Midlife Health (2010) 1.25
Clinical decision support tools for osteoporosis disease management: a systematic review of randomized controlled trials. J Gen Intern Med (2008) 1.19
Validation of the Dutch guidelines for dual X-ray absorptiometry measurement. Br J Gen Pract (2009) 1.16
Usability evaluation of a clinical decision support tool for osteoporosis disease management. Implement Sci (2010) 1.06
Calibration of FRAX ® 3.1 to the Dutch population with data on the epidemiology of hip fractures. Osteoporos Int (2011) 1.02
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J (2015) 0.98
FATIGUE OF BIOMATERIALS: HARD TISSUES. Int J Fatigue (2010) 0.94
Community-based randomised controlled trial evaluating falls and osteoporosis risk management strategies. Trials (2008) 0.93
Risk factors for nonvertebral fracture in obese older women. J Clin Endocrinol Metab (2011) 0.92
Community based intervention to optimize osteoporosis management: randomized controlled trial. BMC Geriatr (2010) 0.91
Abandoned acid? Understanding adherence to bisphosphonate medications for the prevention of osteoporosis among older women: a qualitative longitudinal study. PLoS One (2014) 0.88
Prevalence of osteoporosis and its association with serum vitamin D level in older people in Amirkola, North of Iran. Caspian J Intern Med (2012) 0.86
The invisible disease: making sense of an osteoporosis diagnosis in older age. Qual Health Res (2011) 0.85
Association between osteoporosis and psoriasis: results from the Longitudinal Health Insurance Database in Taiwan. Osteoporos Int (2012) 0.85
Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. J Neurol (2011) 0.85
Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis. J Neurol (2009) 0.84
Advancing maternal age is associated with lower bone mineral density in young adult male offspring. Osteoporos Int (2011) 0.81
Poor histological healing of a femoral fracture following 12 months of oestrogen deficiency in rats. Osteoporos Int (2013) 0.79
Association between delivery at an advanced maternal age and osteoporosis in elderly Korean women. J Bone Miner Metab (2014) 0.78
Bone health nutrition issues in aging. Nutrients (2010) 0.77
Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene. Clin Interv Aging (2008) 0.76
Is PPARγ a prospective player in HIV-1-associated bone disease? PPAR Res (2009) 0.75
Assessment of bone densitometry in Iranian patients with multiple sclerosis: A case-control study. Iran J Neurol (2013) 0.75
The Association between Coffee Consumption and Bone Status in Young Adult Males according to Calcium Intake Level. Clin Nutr Res (2016) 0.75
NICE: Its Influence in Treating Osteoporosis in the UK and beyond. Ther Adv Musculoskelet Dis (2009) 0.75
Strontium ions substitution in brushite crystals: the role of strontium chloride. J Funct Biomater (2011) 0.75
Disease Systems Analysis of Bone Mineral Density and Bone Turnover Markers in Response to Alendronate, Placebo, and Washout in Postmenopausal Women. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
Structural strength of cancellous specimens from bovine femur under cyclic compression. PeerJ (2016) 0.75
What of Asian, African, and South American patients? BMJ (2007) 0.75
Comparison of the efficacy of three once-weekly bisphosphonates on bone mineral density gains in Korean women. Obstet Gynecol Sci (2013) 0.75
Risk and clinical predictors of osteoporotic fracture in East Asian patients with chronic obstructive pulmonary disease: a population-based cohort study. PeerJ (2016) 0.75
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser (1994) 17.37
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Epidemiology and outcomes of osteoporotic fractures. Lancet (2002) 13.09
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Diagnosis of osteoporosis and assessment of fracture risk. Lancet (2002) 7.38
Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res (2000) 7.29
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA (2005) 5.95
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Prevention of falls in the elderly trial (PROFET): a randomised controlled trial. Lancet (1999) 5.37
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res (1992) 4.75
Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med (2004) 3.93
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int (2001) 3.23
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Weight-bearing exercise and bone mineral accrual in children and adolescents: a review of controlled trials. Bone (2006) 2.52
Sex steroids and bone. Physiol Rev (2001) 1.88
Compliance with osteoporosis therapy is the weakest link. Lancet (2006) 1.84
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int (2004) 1.48
Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif Tissue Int (2006) 1.24
Diagnosis and epidemiology of osteoporosis. Curr Opin Rheumatol (2005) 1.07
Intervention thresholds for osteoporosis. Bone (2002) 0.90
The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int (2000) 0.89
How to manage osteoporosis after the menopause. Best Pract Res Clin Rheumatol (2005) 0.86
Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (2013) 5.93
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2008) 2.57
Bisphosphonates in the treatment of osteoporosis. BMJ (2012) 2.21
Histomorphometric analysis of bone biopsies from the iliac crest of adults with cystic fibrosis. Am J Respir Crit Care Med (2002) 1.90
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc (2010) 1.62
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
The association between fracture and obesity is site-dependent: a population-based study in postmenopausal women. J Bone Miner Res (2012) 1.58
Evidence supporting a role of glucocorticoids in short-term bone loss in burned children. Osteoporos Int (2004) 1.52
Loci for regulation of bone mineral density in men and women identified by genome wide linkage scan: the FAMOS study. Hum Mol Genet (2005) 1.42
Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). J Clin Endocrinol Metab (2014) 1.41
Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res (2012) 1.29
Predicting fractures in an international cohort using risk factor algorithms without BMD. J Bone Miner Res (2011) 1.22
The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr (2004) 1.19
Influence of LRP5 polymorphisms on normal variation in BMD. J Bone Miner Res (2004) 1.14
European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros (2011) 1.12
Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab (2007) 1.08
The association between fracture site and obesity in men: a population-based cohort study. J Bone Miner Res (2013) 1.08
An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW). Ann Rheum Dis (2012) 1.06
Frailty and fracture, disability, and falls: a multiple country study from the global longitudinal study of osteoporosis in women. J Am Geriatr Soc (2013) 1.05
Differing risk profiles for individual fracture sites: evidence from the Global Longitudinal Study of Osteoporosis in Women (GLOW). J Bone Miner Res (2012) 1.05
Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice. J Clin Densitom (2011) 1.00
Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2011) 0.96
Characteristics associated with anti-osteoporosis medication use: data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort. Bone (2012) 0.95
Biochemical markers of bone turnover - uses and limitations. Ann Clin Biochem (2014) 0.94
Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax (2007) 0.92
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res (2016) 0.91
Relationship between mortality and BMI after fracture: a population-based study of men and women aged ≥40 years. J Bone Miner Res (2014) 0.90
Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study. Br J Haematol (2003) 0.89
Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. J Cyst Fibros (2009) 0.88
PTHR1 polymorphisms influence BMD variation through effects on the growing skeleton. Calcif Tissue Int (2007) 0.87
Could strontium ranelate have a synergistic role in the treatment of osteoporosis? J Bone Miner Res (2009) 0.87
Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model. Arch Osteoporos (2011) 0.86
Osteoclastogenesis during infective exacerbations in patients with cystic fibrosis. Am J Respir Crit Care Med (2006) 0.85
Estrogen stimulates differentiation of megakaryocytes and modulates their expression of estrogen receptors alpha and beta. J Cell Biochem (2004) 0.85
Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom (2011) 0.84
Characterization of osteocrin expression in human bone. J Histochem Cytochem (2005) 0.83
Obesity, health-care utilization, and health-related quality of life after fracture in postmenopausal women: Global Longitudinal Study of Osteoporosis in Women (GLOW). Calcif Tissue Int (2014) 0.83
Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol (2002) 0.83
Effects of a single infusion of pamidronate prior to liver transplantation: a bone histomorphometric study. Transpl Int (2002) 0.78
Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis. J Cyst Fibros (2011) 0.78
(18)F-fluoride positron emission tomography measurements of regional bone formation in hemodialysis patients with suspected adynamic bone disease. Calcif Tissue Int (2013) 0.76
FRAX(®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. J Clin Densitom (2011) 0.76
Effects of estrogen on collagen synthesis by cultured human osteoblasts depend on the rate of cellular differentiation. J Cell Biochem (2002) 0.75
Bone: Risk of osteoporotic fractures in irritable bowel syndrome. Nat Rev Endocrinol (2012) 0.75
Hydrocortisone increases the rate of differentiation of cultured human osteoblasts. J Cell Biochem (2004) 0.75
The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture. Med Decis Making (2009) 0.75
Testing for secondary causes of osteoporosis. BMJ (2010) 0.75